Sandra Cantilena
London, ENG WC1N1EH, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor.
Journal: Cancers
Published: October 23, 2024
Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes.
Journal: Experimental hematology & oncology
Published: July 03, 2024
FDA-approved disulfiram as a novel treatment for aggressive leukemia.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: May 26, 2023
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Journal: Clinical and translational medicine
Published: February 15, 2022
Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
Journal: Leukemia
Published: November 26, 2021
Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
Journal: Cell death & disease
Published: February 17, 2021
A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 28, 2015
Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
Journal: The Journal of biological chemistry
Published: January 31, 2013
Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 17, 2013
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
Journal: Oncotarget
Published: May 24, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026